December 22, 2025 7:18am

After new highs, I believe it’s time to wish BYE to SOME; it’s been a year and months of share pricing extremes for the cell and gene therapy sector

A holiday shortened week

Pre-open Signals: 1 Negative and 6 Positive Indications

As I have written; “It’s been a good clue to be reducing “some” exposures in a strength market, exiting some also-rans or questionable data delays”

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t! 

 

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! Revenue from collaborations and runways have become indications of sustainability.

 

Friday’s RMi Closing Bell: Witching expiration “covering” drives volatility … https://www.regmedinvestors.com/articles/14238

RMi Research Note: Capricor Therapeutics (CAPR) I am NOT the ONLY dissenter … https://www.regmedinvestors.com/articles/14233

 

Monday: The pre-open Dow futures are UP +0.07% or (+36 points), the S&P futures are UP +0.36% or (+25 points) and the Nasdaq futures are UP +0.54% or (+137 points)

  • Stock futures rose on Monday, 12/22 coming off a mixed week,
  • European markets are lower,
  • Asia Pacific markets traded higher.

Economic Data: Chicago Fed national activity index, September (-0.20 expected)

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed UP +183.04 points or +0.38%, the S&P closed UP +59.74 points or +0.88% while the Nasdaq closed UP +301.26 points or +1.31%
  • Thursday: The Dow closed UP +65.88 points or +0.14%, the S&P closed UP +53.34 points or +0.79% while the Nasdaq closed UP +313.038 points or +1.38%
  • Wednesday: The Dow closed DOWN -228.29 points or -0.47%, the S&P closed DOWN -78.75 points or -1.16% while the Nasdaq closed DOWN -418.139 points or -1.81%
  • Tuesday: The Dow closed DOWN -302.30 points or -0.62%, the S&P closed DOWN -16.25 points or -0.24 % while the Nasdaq closed UP +54.049 points or +0.23%
  • Monday: The Dow closed DOWN -41.31 points or -0.09%, the S&P closed DOWN -10.90 points or -0.16 % while the Nasdaq closed DOWN -137.757 points or -0.59%
  • Last week: The S&P 500 was up +0.1%, the Dow slipped -0.7% and the Nasdaq was up +0.5%.
  • The previous week: The S&P 500 was up +0.3%, the Dow +0.5% and the Nasdaq +0.9%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 6 positive and 9 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I measure the Friday’s 10 highest and lowest in the aftermarket with on-coming pre-open to stimulate an indication

Alnylam Pharmaceuticals (ALNY) closed up +$4.19 after Thursday’s +$3.94 after Wednesday’s +$0.93 with a positive +$1.71 or +0.42% pre-open

Moderna (MRNA) closed up +$2.85 after Thursday’s +$0.44 after Wednesday’s +$0.62 with a negative -$0.08 or -or -0.24% pre-open

Supernus Therapeutics (SUPN) closed up +$2.20 after Thursday’s +$0.53 after Wednesday’s +$0.43 after Tuesday’s +$1.04 after Monday’s +$0.42 with a positive +$0.62 or +1.20% pre-open

Ionis Pharmaceuticals (IONS) closed up +$1.94 after Thursday’s +$0.55 after Wednesday’s -$1.29 after Tuesday’s -$1.39 after Monday’s -$1.21 with a positive +$0.40 or +0.50% pre-open

Arrowhead Pharma (ARWR) closed up +$1.69 after Thursday’s +$1.67 after Wednesday’s +$0.14 after Tuesday’s -$3.79 after Monday’s -$1.51 with a positive +$1.29 or +1.89% pre-open

BioNTech (BNTX) closed up +$1.04 after Thursday’s -$0.14 after Wednesday’s -$0.63 after Tuesday’s -$1.52 after Monday’s -$0.77 with a positive +$0.83 or +0.90% pre-open

CRISPR Therapeutics (CRSP) closed up +$1.09 with a positive +$0.84 or +1.505% pre-open

 

The BOTTOM LINE: Drifting or riding the witches broom?

 The vertigo-inducing swings … can be seen in the Cboe Volatility Index (VIX) measures anticipated price moves in stocks.

  • On April 8, it soared to above 50 for the first time since the pandemic and just the second time since the financial crisis.
  • Then falling below 20 by May, where it’s currently sitting. <Bloomberg>

All 3 major indexes seem to enter the final 7 trading sessions of 2025 within 3% of their record highs.

  • In the week ahead, those investors still around during the holidays will turn their attention to the prospects of a “Santa Claus rally,” while a few pieces of economic data out on Tuesday will clean up some of the lagging data delayed as a result of the government shutdown.
  • Tuesday morning’s read on consumer confidence from the Conference Board should be the key focus, with one of 2025’s defining narratives centering on the K-shaped economy that has emerged among American shoppers.

Markets in the US will be open for half a day on Wednesday and closed on Thursday for Christmas. Many international markets will remain closed on Friday as well. <Yahoo Finance>

Welcome to my world of defining the “grey’ in our universe!

  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

 

4th and final and short week of December to include Christmas holiday

  • Monday: many try to end the week early
  • Tuesday, most exit, travel earlier
  • Wednesday, NYSE closing early pre the eve
  • Thursday: Christmas
  • Friday: many stay home and un-evolved

3rd week of December, my covered sector sector:

  • 12/19 - Friday closed positive with 27 positive, 10 negative and 3 flats
  • 12/18 – Thursday closed positive with 22 positive, 16 negative and 2 flats
  • 12/17 – Wednesday closed negative with 12 positive, 26 negative and 2 flats
  • 12/16- Tuesday closed negative with 17 positive, 21 negative and 2 flats
  • 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats

2nd week:

  • 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

1st week:

  • 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.